



30th Annual Cancer Progress Conference
May 7-8, 2019
Convene, 32 Old Slip, NYC

May 7, 2019

Registration and Continental Breakfast

Opening Remarks

Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health

Keynote:

Rachel Haurwitz, PhD, Chief Executive Officer and Founder, Caribou

Has the Time Come for Chemo- & Immuno- Prevention: Nixing the Nabobs of Negativity?

Panelists

- Michael B. Sporn, MD, Professor of Pharmacology and Medicine/Molecular and Systems Biology/Active Emeritus, Dartmouth Medical School
- William C. Watt, PhD, President and Chief Executive Officer, EpiThany

Networking Break

Novel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New

Panelists:

- Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor of Molecular Biology, Princeton University
- Tim van Hauwermeiren, MSc., MBA, Chief Executive Officer, arGEN-X
- Maurice Zauderer, PhD, President & Chief Executive Officer, Vaccinex, Inc.
- TBD, Vuja De

Networking Luncheon

Basket Trials Revisited: Faster, Better, Smarter Trials/Precision Medicine: Insights and Remaining Challenges, Perspectives from Academia, Pharma and Biotech

Panelists

- Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Onc & Dept of Molecular & Experimental Medicine, Avera Cancer Institute



Networking Break

IO Session I: Combination Failures & Futures: Much Ado About What?

Moderator: Jeff Bockman, PhD, Executive Vice President, Oncology Practice Head, Defined Health

Panelists

- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Axel Hoos, MD, PhD, SVP Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
- Ramy Ibrahim, MD, Vice President and Head of Research & Development, Parker Institute
- Robert Stein, MD, PhD, Senior R&D Advisor, Agenus
- Mai-Britt Zocca, MD, PhD, MBA, Chief Executive Officer, IO Biotech

Cancer Progress 2019 Reception

May 8, 2019

Registration and Continental Breakfast

Opening Remarks: Review of Day 1

Mike Rice, MS, MBA, Principal, Defined Health

Payer/Access Panel

Moderator: Ed Saltzman, Executive Chairman, Defined Health

Panelists

- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Roger Longman, Chief Executive Officer, Real Endpoints

IO Session II: IO Targets and Platforms- Target Versus Modality- What Are the Keys to the Kingdom?

Moderator: Joel Sandler, PhD, Associate Principal, Defined Health

Panelists

- Ramy Ibrahim, MD, Vice President and Head of Research & Development, Parker Institute
- Louis Matis, MD, SVP and Chief Development Officer, Pieris Pharmaceuticals
- Dan Shoemaker, PhD, CSO, Fate Therapeutics





- Harpreet Singh, PhD, Chief Scientific Officer and Managing Director, Immatics Biotechnologies

Networking Break

Gynecological & Breast Cancers, How Novel Therapies from PARPs to Immunotherapies Are Transforming Care: Much Progress, Much to Do

Panelists

- Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Onc & Dept of Molecular & Experimental Medicine, Avera Cancer Institute
- Dmitry Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center

Biotech Deal-Making in the Face of IO Frenzy or Fatigue: Same Old or Difference New?

Panelists

- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- John Haurum, MD, PhD, Chief Executive Officer, f-Star Biotech
- Axel Hoos, MD, PhD, SVP Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
- Helen Tayton-Martin, PhD, MBA, Chief Business Officer, Adaptimmune
- Annette Matthies, PhD, Vice President, Corporate Development, EFFECTOR Therapeutics

Networking Lunch

Heme Malignancies

Moderator: Mike Rice, MS. MBA, Principal, Defined Health

Panelists

- x

Oncology Innovation Powered by Investments and Competition from China

Moderator: James Lee, PhD, Associate Principal, Oncology Lead, Defined Health

Panelists

- Ji Li, PhD, Venture Partner, Lilly Asia Ventures
- Weimin Tang, PhD, Executive Vice President and Global Business Head, I-Mab Biopharma

Cancer Progress 2019 Conference Concludes

